Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy.
|Abstract||To evaluate clinical outcomes of concurrent chemoradiotherapy (CCRT) in patients with hypopharyngeal cancer (HPC).|
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
|Journal Title||anticancer research|
|Publication Year Start||2017-01-01|
PMID- 28179356 OWN - NLM STAT- MEDLINE DA - 20170209 DCOM- 20170306 LR - 20170306 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 37 IP - 2 DP - 2017 Feb TI - Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy. PG - 941-947 AB - AIM: To evaluate clinical outcomes of concurrent chemoradiotherapy (CCRT) in patients with hypopharyngeal cancer (HPC). PATIENTS AND METHODS: This retrospective study included 80 patients (75 males) aged 48 to 78 years (median=66 years) with a histological diagnosis of HPC. The 5-fluorouracil and cisplatin (FP) regimen was used until 2007 and then switched to the docetaxel, cisplatin, and 5-fluorouracil (TPF) regimen. Radiotherapy was administered to a total dose of 60 to 72 Gy (median=66 Gy). RESULTS: The 5-year overall survival and disease-free survival rates were 49.3% and 60.7%, respectively. Improved disease-free survival was associated with lower N-stage (hazard ratio=0.249; 95% confidence interval=0.096-0.643; p=0.041). CONCLUSION: There were no significant differences in overall and disease-free survival between patients receiving CCRT with the TPF regimen and those who received FP for a long period of treatment but did not finish two courses. CI - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Sakaguchi, Masakuni AU - Sakaguchi M AD - Department of Radiology, Nihon University School of Medicine, Tokyo, Japan firstname.lastname@example.org. FAU - Maebayashi, Toshiya AU - Maebayashi T AD - Department of Radiology, Nihon University School of Medicine, Tokyo, Japan. FAU - Aizawa, Takuya AU - Aizawa T AD - Department of Radiology, Nihon University School of Medicine, Tokyo, Japan. FAU - Ishibashi, Naoya AU - Ishibashi N AD - Department of Radiology, Nihon University School of Medicine, Tokyo, Japan. FAU - Saito, Tsutomu AU - Saito T AD - Sonodakai Radiation Oncology Clinic, Tokyo, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (Taxoids) RN - 15H5577CQD (docetaxel) RN - Q20Q21Q62J (Cisplatin) RN - U3P01618RT (Fluorouracil) SB - IM MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use MH - Chemoradiotherapy/adverse effects/methods MH - Cisplatin/administration & dosage/adverse effects MH - Deglutition Disorders/etiology MH - Disease-Free Survival MH - Female MH - Fluorouracil/administration & dosage/adverse effects MH - Humans MH - Hypopharyngeal Neoplasms/*drug therapy/pathology/*radiotherapy MH - Male MH - Middle Aged MH - Mucositis/etiology MH - Multivariate Analysis MH - Neoplasm Staging MH - Neoplasms, Second Primary/etiology MH - Neutropenia/etiology MH - *Radiotherapy Dosage MH - Retrospective Studies MH - Taxoids/administration & dosage/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - Concurrent chemoradiotherapy OT - hypopharyngeal cancer OT - radiotherapy EDAT- 2017/02/10 06:00 MHDA- 2017/03/07 06:00 CRDT- 2017/02/10 06:00 PHST- 2016/12/18 [received] PHST- 2017/01/26 [revised] PHST- 2017/01/27 [accepted] AID - 37/2/941 [pii] AID - 10.21873/anticanres.11403 [doi] PST - ppublish SO - Anticancer Res. 2017 Feb;37(2):941-947.
<?xml version="1.0" encoding="UTF-8"?> <b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" > </b:Sources>